

ACCEPTANCE OF EVEROLIMUS' PHARMACOKINETIC RECOMMENDATIONS IN RENAL TRANSPLANT PATIENTS

Rochina Astorga A, Gutiérrez Palomo S, González Fernández A, García Monsalve A, Soriano Irigaray L, Navarro Ruiz A.
Hospital General Universitario Elche

OBJECTIVES:

To assess the degree of acceptance by the Nephrology service of recommendations made by the Clinical Pharmacokinetics Unit after monitoring of everolimus blood concentrations (CSE) at a General Hospital Third-level university.

MATERIAL AND METHODS:

Retrospective observational study (January 2016 and September 2019) in renal transplant patients



Variables (collected from GestLab®):
age, sex, date of testing, concomitant immunosuppressive treatment, pharmacokinetic recommendation and blood drug concentration


Target range everolimus (ng/mL):
monotherapy 6-10
combination with calcineurin inhibitors 3-8

RESULTS:



49 patients

59% men
60 ± 12 years
9 ± 5,3 determinations



Recommendation accepted (69%)

Recommendation not accepted (31%)



443 determinations

34,3%

Overdosed (OD) = 11,3%

Underdosed (UD) = 23%

In range = 65,7%



In range = 66%

OD/UD = 34%

CONCLUSION AND RELEVANCE:

During the study period, posology individualization was necessary in almost 35% of the analyzes performed by the Clinical Pharmacokinetics Service, being the pharmacokinetic recommendations accepted by the prescriber in more than 60% of cases.